Keytruda (pembrolizumab) is an immune checkpoint inhibitor that targets the PD-1 receptor on T-cells, blocking its interaction with PD-L1 and PD-L2, which are often upregulated on tumor cells to evade immune surveillance. This evidence concerns the gene CD274 and neoplasm.